Immunotherapy

Leukemia/Lymphoma/Hematologic

Joint Session 01 - ASTRO-ILROG Joint Session:?Riding the Tsunami: The Role and Practice of Radiation Therapy for Hematological Malignancies in the New Era of Biologicals, Immunotherapies (Checkpoint Inhibitors and CAR-T Cells)

10/21/2018
1:15 PM - 2:45 PM
Location: Room 214 C/D

Session Type: Workshop/Special Session
1.50 AMA PRA Category 1 Credits™
1.50 CAMPEP Credits
1.50 MDCB Credits

This session was proudly submitted as a joint session with International Lymphoma Radiation Oncology Group (ILROG).
This session will address:
1.The new biological agents with emphasis of immunotherapy's role in the spectrum of hematological malignancies, particularly Hodgkin's lymphoma and NHL. Status of FDA approval and effects on clinical practice.
2. The options and caveats of integrating radiotherapy
3. New research ideas, experimental models and current clinical protocols testing augmentation of immunotherapy effects (including CAR-T cells), abscopal and "vaccine" effects of RT.

Learning Objectives:

Presentations:

Joachim Yahalom, MD, FASTRO

Memorial Sloan Kettering Cancer Center

Disclosure:
Employment
Memorial Sloan Kettering Cancer Center: Attending and Member: Employee

Presentation(s):

Send Email for Joachim Yahalom


Assets

Joint Session 01 - ASTRO-ILROG Joint Session:?Riding the Tsunami: The Role and Practice of Radiation Therapy for Hematological Malignancies in the New Era of Biologicals, Immunotherapies (Checkpoint Inhibitors and CAR-T Cells)



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Joint Session 01 - ASTRO-ILROG Joint Session:?Riding the Tsunami: The Role and Practice of Radiation Therapy for Hematological Malignancies in the New Era of Biologicals, Immunotherapies (Checkpoint Inhibitors and CAR-T Cells)